2. Clindamycin

Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria.

For research use only. We do not sell to patients.

Clindamycin Chemical Structure

Clindamycin Chemical Structure

CAS No. : 18323-44-9

Size Price Stock Quantity
5 mg USD 25 In-stock
10 mg USD 30 In-stock
25 mg USD 50 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Clindamycin:

Clindamycin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • Customer Review

Description

Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2].

IC50 & Target

MIC Tatget:Clindamycin[4] MIC: 200 μg/mL (E. coli)[4]
In Vitro

Clindamycin (25 μg/mL, 1-18 h) inhibits ceftazidime (HY-B0593)-induced endotoxin release pretreatment in E. coli O55:B5[3].
Clindamycin (50-100 μg/mL, 0-12 min) enhances antibody- and complement-dependent phagocytosis in Staphylococcus aureus[4].
Clindamycin (0-500 μg/mL, 24-72 h) inhibits the cell proliferation in osteoblast cell culture model, stimulates the cell metabolism of osteoblast at the contratibution of 10 μg/mL[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clindamycin Related Antibodies

Cell Viability Assay[3]

Cell Line: THP-1 cells with stimulated E. coli O55:B5
Concentration: 3.13-50 μg/mL
Incubation Time: 1-18 h
Result: Reduced TNF-α concentrations after pretreatment for 4 or 18 h at 25 and 50 μg/mL.

Cell Viability Assay[5]

Cell Line: Osteoblast cell culture model
Concentration: 0-500 μg/mL
Incubation Time: 24-72 h
Result: Increased alkaline phosphatase (ALP)-activity at 10 μg/mL at 24 and 48 h.
Increased LDH values at 500 μg/mL at 24 and 48 h, indicating cytotoxicity.
Increased calcification at 10 and 25 μg/mL,decreased or no calcification was found at 50 μg/ml.
In Vivo

Clindamycin (50-300 mg/kg; i.v., p.o.) dosage doesn’t affect pharmacokinetic parameters in rats[6].
Clindamycin (160-600 mg/kg; i.v.) improves survival in a dose-dependent manner in endotoxic shock mouse model[7].
Clindamycin (17-50 mg/kg, i.v.) has good penetration into rat muscle tissue that can be applied to inhibit the main bacteria causing odontogenic infections[8].
1.19
Pharmacokinetic Analysis in Rat Model[8]

Route Dose (mg/kg) t1/2 (h) Cmax (mg/mL) Tmax (h)a AUC0-inf (h.mg/L) ∱T
i.v. 51(Plasma) 2.51 (2.37–2.83) 35.21 (25.04–42.65) 0.08 ± 0.00 44.78 (28.82–65.65) /
i.v. 51(Tissue) 2.82 (2.57–3.05) 14.20 (10.63–14.89) 0.25 ± 0.00 16.54 (13.83–18.35) 1.10
i.v. 17(Tissue) 3.25 (3.13–3.44) 4.82 (3.35–6.66 0.25 ± 0.00 / /

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Endotoxic shock mouse model[7]
Dosage: 160-600 mg/kg
Administration: Intravenous injection (i.v.)
Result: Decreased survival rates to 92 and 36% treated with 520- and 600-mg/kg doses.
Lowered the peak concentrations of tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) in serum.
Increased the the peak concentrations of IL-6 in the sera.
Clinical Trial
Molecular Weight

424.98

Formula

C18H33ClN2O5S
CAS No.
Appearance

Solid

Color

White to light yellow

SMILES

CN(C[C@H](CCC)C1)[C@@H]1C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 125 mg/mL (294.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3531 mL 11.7653 mL 23.5305 mL
5 mM 0.4706 mL 2.3531 mL 4.7061 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 98.49%

COA (256 KB) HNMR (261 KB) LCMS (92 KB)

Handling Instructions (2659 KB)

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3531 mL 11.7653 mL 23.5305 mL 58.8263 mL
5 mM 0.4706 mL 2.3531 mL 4.7061 mL 11.7653 mL
10 mM 0.2353 mL 1.1765 mL 2.3531 mL 5.8826 mL
15 mM 0.1569 mL 0.7844 mL 1.5687 mL 3.9218 mL
20 mM 0.1177 mL 0.5883 mL 1.1765 mL 2.9413 mL
25 mM 0.0941 mL 0.4706 mL 0.9412 mL 2.3531 mL
30 mM 0.0784 mL 0.3922 mL 0.7844 mL 1.9609 mL
40 mM 0.0588 mL 0.2941 mL 0.5883 mL 1.4707 mL
50 mM 0.0471 mL 0.2353 mL 0.4706 mL 1.1765 mL
60 mM 0.0392 mL 0.1961 mL 0.3922 mL 0.9804 mL
80 mM 0.0294 mL 0.1471 mL 0.2941 mL 0.7353 mL
100 mM 0.0235 mL 0.1177 mL 0.2353 mL 0.5883 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Clindamycin18323-44-9Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Clindamycin
Cat. No.:
HY-B1455
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.